Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07713719

Arterial Stiffness and Endothelial Function in Heart Failure

Arterial Stiffness and Endothelial Function in Heart Failure — Recruiting • Cardiology / Cardiovascular • NCT07713719.

📅 21 Oct 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07713719
Sponsor
Coventry University
Start
2026-09-18
ClinicaliQ Trial Snapshot
  • Arterial Stiffness and Endothelial Function in Heart Failure — Recruiting • Cardiology / Cardiovascular • NCT07713719.
  • What is being tested: The study investigates how arterial stiffness and endothelial dysfunction contribute to poor outcomes in heart failure patients, aiming to identify vascular mechanisms that may explain persistent clinical deterioration despite current treatments.
  • Patient eligibility overview: The trial recruits heart failure patients across the disease spectrum; specific eligibility criteria determine which patients can participate, allowing researchers to assess vascular function in this heterogeneous population.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Heart Failure (HF) is a global condition affecting at least 26 million people worldwide. Despite advances in treatment, HF patients continue to experience poor health outcomes. This study aims to improve understanding of the role of blood vessels in people with heart failure. The study will assess how arterial stiffness (how stiff blood vessels are) and endothelial function (how well the lining of blood vessels functions) change over time and respond to treatments received as part of routine clinical care. Blood vessel function and heart performance will be assessed at…

Eligibility Snapshot
  • : * Male and female ≥ 18 years old. * Have a confirmed de-novo diagnosis of Heart failure with preserved ejection fraction or Heart failure with reserved ejection fraction. Common HF phenotypes (e.g., hypertension, diabetes, obesity) will be recorded as part of routine baseline data but will not influence recruitment or sampling. . * Have stable Heart failure in the opinion of the investigator. * Have ability, in the opinion of the investigator, to participate in study activities. * Able to provide written informed consent.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Clinical Brief
New heart disease and strokes plan to saves thousands of lives
Cardiology / Cardiovascular · NHS England · 07 Jul 2026
A new national framework aims to reduce premature deaths from heart disease and strokes by 25% over the next decade, requiring implementation…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Clinical Brief
The children dying in India’s remote tribal heartland
Cardiology / Cardiovascular · BBC Health · 30 Sep 2026
Measles and malaria resurgence in vulnerable populations: At least 32 child deaths in Balaghat district highlight ongoing risks in remote tribal areas…
View brief →